Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Managed care controls could allow for more relaxed FDA approval standards, Covance exec maintains.

Executive Summary

MANAGED CARE DRUG CONTROLS MAKE ACCELERATED APPROVAL ACCEPTABLE MODEL for a larger number of FDA reviews, Covance Senior Scientific Officer William Wardell, MD/PhD, maintained at a July 18 Capitol Hill briefing on an Institute for Alternative Futures report, "Clinical Development 2005." Managed care "with its utilization controls, its databases and potential for quick follow-up has really transformed the landscape [of drug monitoring] and possibly made some of our strictest controls redundant," Wardell suggested.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030590

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel